SWK (SWKH) Q2 2024 earnings summary

Executive summary

• Q2 2024 revenue increased 21% year-over-year to $11.5 million, driven by higher interest, fees, and pharmaceutical development revenue.

• GAAP net income for Q2 2024 was $4.4 million, up from $3.9 million in Q2 2023, with diluted EPS of $0.35.

• Finance Receivables segment generated $6.5 million adjusted non-GAAP net income, with a 19% year-over-year portfolio growth to $267 million.

• Pharmaceutical Development (Enteris) revenue nearly tripled sequentially to $800,000, supported by strategic partnerships and guaranteed payments.

• Both segments contributed to overall revenue growth, with a focus on financing commercial-stage life science companies.

Financial highlights

• Q2 2024 net income: $4.4 million; revenue: $11.5 million; EPS: $0.35.

• Net finance receivables reached $265.5 million as of June 30, 2024, up 19% year-over-year.

• Provision for credit losses was $4.1 million, with $5.8 million impairment on the Cara license and $4.3 million in loan impairments.

• Book value per share as of June 30, 2024: $22.75 GAAP (up 4.4%), $20.17 non-GAAP (up 6.4%).

• $2.5 million gain from Illuvien royalty revaluation and $0.7 million gain from AOTI warrant conversion.

Outlook and guidance

• Management expects both finance receivables and pharmaceutical development segments to generate positive cash flows in 2024.

• Focus remains on closing additional loan and royalty financings and supporting Enteris partnerships.

• Enteris business is positioned to be cash flow break even or better through the strategic partnership period.